+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030- Product Image
Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 5649386
Description Jump to:

Stomach Cancer Treatment Market Growth & Trends

The global stomach cancer treatment market size is estimated to reach USD 11.19 billion by 2030, registering to grow at a CAGR of 12.5% from 2025 to 2030 . Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics’ drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights

  • Targeted therapy dominated the market and accounted for a share of 39.6% in 2024. Targeted therapy offers precision targeting cancer cells while minimizing harm to adjacent healthy tissues.
  • Gastric cancer/gastroesophageal junction led the market with a revenue share of 84.7% in 2024, fueled by its considerable prevalence and associated mortality rates worldwide.
  • Injectable treatment held the largest revenue share of 89.0% in 2024, aided by their rapid therapeutic action and effectiveness in administering chemotherapy and targeted therapies directly into the bloodstream.
  • VEGFR antagonists held a substantial share in 2024 due to their critical role in inhibiting tumor angiogenesis, a vital process for tumor growth and metastasis.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment Type
1.2.2. Disease Indication
1.2.3. Route of Administration
1.2.4. Drug Class
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Stomach Cancer Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Stomach Cancer Treatment Market: Treatment Type Business Analysis
4.1. Treatment Type Market Share, 2024 & 2030
4.2. Treatment Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Million)
4.4. Standard Chemotherapy
4.4.1. Standard Chemotherapy Market, 2018 - 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
4.6. Immunotherapy
4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
Chapter 5. Stomach Cancer Treatment Market: Disease Indication Business Analysis
5.1. Disease Indication Market Share, 2024 & 2030
5.2. Disease Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
5.4. Gastric Cancer/Gastroesophageal Junction Cancer
5.4.1. Gastric Cancer/Gastroesophageal Junction Cancer Market, 2018 - 2030 (USD Million)
5.5. Gastrointestinal Stromal Tumors
5.5.1. Gastrointestinal Stromal Tumors Market, 2018 - 2030 (USD Million)
Chapter 6. Stomach Cancer Treatment Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
6.4.1. Oral Market, 2018 - 2030 (USD Million)
6.5. Injectable
6.5.1. Injectable Market, 2018 - 2030 (USD Million)
Chapter 7. Stomach Cancer Treatment Market: Drug Class Business Analysis
7.1. Drug Class Market Share, 2024 & 2030
7.2. Drug Class Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
7.4. PD-1/PD-L1 Inhibitors
7.4.1. PD-1/PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
7.5. HER2 Antagonists
7.5.1. HER2 Antagonists Market, 2018 - 2030 (USD Million)
7.6. VEGFR Antagonists
7.6.1. VEGFR Antagonists Market, 2018 - 2030 (USD Million)
7.7 Others
7.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. Stomach Cancer Treatment Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Thailand Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Novartis AG
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Pfizer Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Mylan N.V.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. F. Hoffmann-La Roche Ltd
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Eli Lilly and Company
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Merck & Co., Inc.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Teva Pharmaceutical Industries Ltd.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. CELLTRION INC.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Samsung Bioepis
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Bristol-Myers Squibb Company
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global stomach cancer treatment market, by region, 2018 - 2030 (USD Million)
Table 4. Global stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 5. Global stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 6. Global stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 7. Global stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 8. North America stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
Table 9. North America stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 10. North America stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 11. North America stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 12. North America stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 13. U.S. stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 14. U.S. stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 15. U.S. stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 16. U.S. stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 17. Canada stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 18. Canada stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 19. Canada stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 20. Canada stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 21. Mexico stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 22. Mexico stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 23. Mexico stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 24. Mexico stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 25. Europe stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
Table 26. Europe stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 27. Europe stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 28. Europe stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 29. Europe stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 30. UK stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 31. UK stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 32. UK stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 33. UK stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 34. Germany stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 35. Germany stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 36. Germany stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 37. Germany stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 38. France stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 39. France stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 40. France stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 41. France stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 42. Italy stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 43. Italy stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 44. Italy stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 45. Italy stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 46. Spain stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 47. Spain stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 48. Spain stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 49. Spain stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 50. Denmark stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 51. Denmark stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 52. Denmark stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 53. Denmark stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 54. Sweden stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 55. Sweden stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 56. Sweden stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 57. Sweden stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 58. Norway stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 59. Norway stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 60. Norway stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 61. Norway stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 62. Asia Pacific stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
Table 63. Asia Pacific stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 64. Asia Pacific stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 65. Asia Pacific stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 66. Asia Pacific stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 67. China stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 68. China stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 69. China stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 70. China stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 71. Japan stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 72. Japan stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 73. Japan stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 74. Japan stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 75. India stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 76. India stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 77. India stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 78. India stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 79. Australia stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 80. Australia stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 81. Australia stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 82. Australia stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 83. South Korea stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 84. South Korea stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 85. South Korea stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 86. South Korea stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 87. Thailand stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 88. Thailand stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 89. Thailand stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 90. Thailand stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 91. Latin America stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
Table 92. Latin America stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 93. Latin America stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 94. Latin America stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 95. Latin America stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 96. Brazil stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 97. Brazil stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 98. Brazil stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 99. Brazil stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 100. Argentina stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 101. Argentina stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 102. Argentina stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 103. Argentina stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 104. Middle East & Africa Stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
Table 105. Middle East & Africa stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 106. Middle East & Africa stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 107. Middle East & Africa stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 108. Middle East & Africa stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 109. South Africa stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 110. South Africa stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 111. South Africa stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 112. South Africa stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 113. Saudi Arabia stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 114. Saudi Arabia stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 115. Saudi Arabia stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 116. Saudi Arabia stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 117. UAE stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 118. UAE stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 119. UAE stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 120. UAE stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
Table 121. Kuwait stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
Table 122. Kuwait stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
Table 123. Kuwait stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 124. Kuwait stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Stomach cancer treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment type and disease indication outlook (USD Million)
Fig. 10 Route of administration and drug class outlook (USD Million)
Fig. 11 Competitive landscape
Fig. 12 Stomach cancer treatment market dynamics
Fig. 13 Stomach cancer treatment market: Porter’s five forces analysis
Fig. 14 Stomach cancer treatment market: PESTLE analysis
Fig. 15 Others market, 2018 - 2030 (USD Million)
Fig. 16 Stomach cancer treatment market: Treatment type segment dashboard
Fig. 17 Stomach cancer treatment market: Treatment type market share analysis, 2024 & 2030
Fig. 18 Standard chemotherapy market, 2018 - 2030 (USD Million)
Fig. 19 Targeted therapy market, 2018 - 2030 (USD Million)
Fig. 20 Immunotherapy market, 2018 - 2030 (USD Million)
Fig. 21 Stomach cancer treatment market: Disease indication segment dashboard
Fig. 22 Stomach cancer treatment market: Disease indication market share analysis, 2024 & 2030
Fig. 23 Gastric cancer/gastroesophageal junction cancer market, 2018 - 2030 (USD Million)
Fig. 24 Gastrointestinal stromal tumors market, 2018 - 2030 (USD Million)
Fig. 25 Stomach cancer treatment market: Route of administration segment dashboard
Fig. 26 Stomach cancer treatment market: Route of administration market share analysis, 2024 & 2030
Fig. 27 Oral market, 2018 - 2030 (USD Million)
Fig. 28 Injectable market, 2018 - 2030 (USD Million)
Fig. 29 Stomach cancer treatment market: Drug class segment dashboard
Fig. 30 Stomach cancer treatment market: Drug class market share analysis, 2024 & 2030
Fig. 31 PD-1/PD-L1 inhibitors market, 2018 - 2030 (USD Million)
Fig. 32 HER2 antagonists market, 2018 - 2030 (USD Million)
Fig. 33 VEGFR antagonists market, 2018 - 2030 (USD Million)
Fig. 34 Stomach cancer treatment market revenue, by region
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 Regional marketplace: Key takeaways
Fig. 37 North America stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 38 U.S. country dynamics
Fig. 39 U.S. stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 40 Canada country dynamics
Fig. 41 Canada stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 42 Mexico country dynamics
Fig. 43 Mexico stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 44 Europe stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 45 UK country dynamics
Fig. 46 UK stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 47 Germany country dynamics
Fig. 48 Germany stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 49 France country dynamics
Fig. 50 France stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 51 Italy country dynamics
Fig. 52 Italy stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 53 Spain country dynamics
Fig. 54 Spain stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 55 Norway country dynamics
Fig. 56 Norway stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 57 Sweden country dynamics
Fig. 58 Sweden stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 59 Denmark country dynamics
Fig. 60 Denmark stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 61 Asia Pacific stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 62 Japan country dynamics
Fig. 63 Japan stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 64 China country dynamics
Fig. 65 China stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 66 India country dynamics
Fig. 67 India stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 68 Australia country dynamics
Fig. 69 Australia stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 70 South Korea country dynamics
Fig. 71 South Korea stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 72 Thailand country dynamics
Fig. 73 Thailand stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 74 Latin America stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 75 Brazil country dynamics
Fig. 76 Brazil stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 77 Argentina country dynamics
Fig. 78 Argentina stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 79 MEA stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 80 South Africa country dynamics
Fig. 81 South Africa stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 82 Saudi Arabia country dynamics
Fig. 83 Saudi Arabia stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 84 UAE country dynamics
Fig. 85 UAE stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 86 Kuwait country dynamics
Fig. 87 Kuwait stomach cancer treatment market, 2018 - 2030 (USD Million)
Fig. 88 Company categorization
Fig. 89 Company market position analysis
Fig. 90 Strategic framework

Companies Mentioned

  • Novartis AG
  • Pfizer Inc.
  • Mylan N.V.
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • CELLTRION INC.
  • Samsung Bioepis
  • Bristol-Myers Squibb Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedDecember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.37 billion
Forecasted Market Value ( USD ) by 2030 $ 11.19 billion
Compound Annual Growth Rate12.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Stomach Cancer Treatment Market by Treatment, Disease Indication, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Stomach Cancer Treatment Market by Treatment, Disease Indication, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Gastric Cancer Drugs Market by Molecule Type, Lines of Chemotherapy, Route of Administration - Global Forecast 2025-2030 - Product Image

Gastric Cancer Drugs Market by Molecule Type, Lines of Chemotherapy, Route of Administration - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
HER2-positive Gastric Cancer - Pipeline Insight, 2024 - Product Image

HER2-positive Gastric Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • 80 Pages
  • Global
From
Gastric Cancer - Pipeline Insight, 2024 - Product Image

Gastric Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • 550 Pages
  • Global
From
Gastric Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Gastric Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 112 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.